Funding News

Piramal Pharma Has Taken Majority Control of Yapan Bio for Rs 76 Crore — A Hyderabad Vaccine and Biologics CDMO Is Now a Piramal Subsidiary

By Mustafa Shariff, Editor in Chief · August 21,2026 · 2 mins read

Mustafa Shariff, Editor in Chief — Piramal Pharma Has Taken Majority Control of Yapan Bio for Rs 76 Crore — A Hyderabad Vaccine and Biologics CDMO Is Now a Piramal Subsidiary

Summary

  • Piramal Pharma Acquires Majority Stake in Yapan Bio for Rs 76 Crore — Hyderabad Vaccine and Biologics CDMO Becomes Piramal Subsidiary
  • Piramal Pharma exercised its call option to acquire an additional 40.67% of Yapan Bio for Rs 76 crore, increasing its stake to 74% and making the Hyderabad vaccine and biologics CDMO a Piramal subsidiary.

"The consolidation of Yapan Bio as a subsidiary significantly strengthens Piramal Pharma Solutions' biologics CDMO offering. Yapan's vaccine and large-molecule capabilities complement our existing ADC payload-linker infrastructure, peptide API manufacturing, and sterile injectables network. Across the biologics value chain, we are now building a genuinely integrated CDMO platform — one that can support vaccine development, biologic drug substance manufacturing, and complex finished product supply. This is the next chapter of Piramal's biologics strategy."

Piramal Pharma Limited has completed the acquisition of an additional 40.67% equity stake in Yapan Bio Private Limited — a Hyderabad-based CDMO specialising in vaccines and biologics — for approximately Rs 76 crore, exercising a call option disclosed to SEBI on August 10, 2026. The transaction, announced August 19, 2026, increases Piramal's shareholding in Yapan from 33.33% to 74.00%, converting Yapan Bio from an associate company to a subsidiary.
What Yapan Bio Brings to Piramal's Platform
Yapan Bio's CDMO capabilities centre on vaccine development and manufacturing and large-molecule biologics — a capability set that complements Piramal's existing infrastructure. BHC Media has covered Piramal's biologics strategy across multiple 2026 editions: the $90M sterile injectables and payload-linker expansion at US facilities (July 8 edition), the Ajinomoto Bio-Pharma ADC partnership (August 3 edition), and the Turbhe spray drying suite for peptides (August 6 edition).
Yapan Bio adds the vaccine CDMO dimension — the ability to support vaccine development programmes from early-stage development through clinical and commercial supply — that Piramal had not previously operated as a dedicated subsidiary. This is strategically significant in the context of India's post-COVID vaccine manufacturing ambition and the biologics-to-vaccines integration that BHC Media covered in the BIRAC-RDI Fund and biopharma SHAKTI contexts.
The Rs 76 Crore Consideration
Piramal acquired 1,46,400 equity shares of Rs 10 each in Yapan from its existing shareholders for an aggregate cash consideration of approximately Rs 76 crore — a valuation that reflects Yapan's pre-revenue or early-revenue stage as a specialised CDMO, where strategic capability value exceeds current financial metrics.
BHC Perspective
For BHC founders in vaccine technology, biologics CDMO, or large-molecule manufacturing — Piramal's systematic biologics platform assembly (ADC infrastructure + peptide capabilities + vaccine CDMO through Yapan) defines the integrated CDMO platform that global vaccine and biologics clients will increasingly require. This is what BIOSECURE Act-era biologics CDMO capability building looks like.
Frequently Asked Questions
Q: What did Piramal acquire?
A: An additional 40.67% stake in Yapan Bio Private Limited for Rs 76 crore, exercising a pre-existing call option. This increases Piramal's total stake from 33.33% to 74%, converting Yapan Bio from an associate to a subsidiary. Yapan Bio is a Hyderabad-based vaccine and biologics CDMO.
Q: Why does this matter for Piramal's strategy?
A: Yapan Bio's vaccine CDMO capabilities complement Piramal's ADC payload-linker infrastructure, peptide API manufacturing, and sterile injectables network — creating a more complete integrated biologics-to-vaccines CDMO platform consistent with Piramal's deliberate strategy of avoiding generic GLP-1 and focusing on high-barrier biologics manufacturing.
Q: What is Piramal's broader biologics build-out?
A: $90M sterile injectables and ADC payload-linker expansion at US facilities; Ajinomoto Bio-Pharma ADC partnership; Turbhe spray drying suite for peptides; and now Yapan Bio vaccine CDMO subsidiary — all executed in 2026 as part of the same biologics platform assembly strategy.